{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:51:00Z","timestamp":1786992660233,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006196","name":"Jet Propulsion Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009094","name":"Russian Humanitarian Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jid.2023.01.040","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T20:27:46Z","timestamp":1680294466000},"page":"1896-1905.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3392-6590","authenticated-orcid":false,"given":"Christine","family":"Bangert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-0349","authenticated-orcid":false,"given":"Christian","family":"Loesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-7124","authenticated-orcid":false,"given":"Hans","family":"Skvara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9114-2351","authenticated-orcid":false,"given":"Regina","family":"F\u00f6lster-Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7663-2053","authenticated-orcid":false,"given":"Jean-Philippe","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3118-6499","authenticated-orcid":false,"given":"Julie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7123-9161","authenticated-orcid":false,"given":"Patrick","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2458-3867","authenticated-orcid":false,"given":"Natalija","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3843-7841","authenticated-orcid":false,"given":"Georg","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.01.040_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jid.2023.01.040_bib2","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1523-1747.2003.12623.x","article-title":"Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease?","volume":"121","author":"Bangert","year":"2003","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.01.040_bib3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.01.040_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1081-1206(10)61221-5","article-title":"Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma","volume":"95","author":"Borish","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2133.2007.08412.x","article-title":"Diagnostic criteria for atopic dermatitis: a systematic review","volume":"158","author":"Brenninkmeijer","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2023.01.040_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00412924","article-title":"The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis","volume":"278","author":"Bruynzeel-Koomen","year":"1986","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2023.01.040_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jid.2023.01.040_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2023.01.040_bib9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib11","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jid.2023.01.040_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/0091-6749(74)90037-2","article-title":"Serum IgE concentration in atopic dermatitis. Relationship to severity of disease and presence of atopic respiratory disease","volume":"54","author":"Johnson","year":"1974","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fimmu.2018.00254","article-title":"Targeting IgE antibodies by immunoadsorption in atopic dermatitis","volume":"9","author":"Kasperkiewicz","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib15","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.4049\/jimmunol.1601476","article-title":"From IgE to omalizumab","volume":"197","author":"Kawakami","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/1523-1747.ep12286482","article-title":"The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients","volume":"108","author":"Klubal","year":"1997","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.01.040_bib17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jid.2023.01.040_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2020.01.002","article-title":"Increasing evidence for omalizumab in the treatment of bullous pemphigoid","volume":"6","author":"Lonowski","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2023.01.040_bib19","unstructured":"Maurer M, Gimenez Arnau A, Sussman G, Saini S, Hide M, Ensina L, et\u00a0al. Efficacy and safety of ligelizumab in patients with chronic spontaneous urticaria: results of two phase 3 randomized controlled trials. Paper presented at: 2022 European Academy of Dermatology and Venereology. 7\u221210 September, 2022; Milan, Italy."},{"key":"10.1016\/j.jid.2023.01.040_bib20","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.01.040_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.01.040_bib22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jaci.2004.05.038","article-title":"Characterization of FcepsilonRI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis","volume":"114","author":"Novak","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jid.2023.01.040_bib24","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jid.2018.09.020","article-title":"Immunoglobulin E-selective immunoadsorption reduces peripheral and skin-bound immunoglobulin E and modulates cutaneous IL-13 expression in severe atopic dermatitis","volume":"139","author":"Reich","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.01.040_bib25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2500\/aap.2008.29.3160","article-title":"Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study","volume":"29","author":"Sheinkopf","year":"2008","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jid.2023.01.040_bib26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000237499","article-title":"IgE-mediated allergen presentation via Fc epsilon Rl on antigen-presenting cells","volume":"113","author":"Stingl","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib28","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib29","doi-asserted-by":"crossref","first-page":"e1255","DOI":"10.1002\/cti2.1255","article-title":"Ligelizumab treatment for severe asthma: learnings from the clinical development programme","volume":"10","author":"Trischler","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.jid.2023.01.040_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2005.12.045","article-title":"Efficacy of anti-IgE therapy in patients with atopic dermatitis","volume":"55","author":"Vigo","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.01.040_bib31","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","article-title":"Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis","volume":"138","author":"Wang","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2023.01.040_bib32","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/all.13716","article-title":"IgE-specific immunoadsorption: new treatment option for severe refractory atopic dermatitis","volume":"74","author":"Wegner","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jid.2023.01.040_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2023.01.040_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2230.2009.03733.x","article-title":"What\u2019s new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 1. Definitions, causes and consequences of eczema","volume":"35","author":"Williams","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2023.01.040_bib35","doi-asserted-by":"crossref","first-page":"100519","DOI":"10.1016\/j.waojou.2021.100519","article-title":"Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence","volume":"14","author":"Wollenberg","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jid.2023.01.040_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2222.1978.tb03220.x","article-title":"Serum IgE in atopic dermatitis: relationship to severity of cutaneous involvement and course of disease as well as coexistence of atopic respiratory diseases","volume":"8","author":"W\u00fcthrich","year":"1978","journal-title":"Clin Allergy"},{"key":"10.1016\/j.jid.2023.01.040_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2340\/00015555-2165","article-title":"Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab","volume":"96","author":"Zink","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2023.01.040_bib38","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1523-1747.2003.12623.x","article-title":"Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease?","volume":"121","author":"Bangert","year":"2003","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.01.040_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:52:35Z","timestamp":1762206755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23019425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0022202X23019425"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.01.040","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}